

Sources and Fates of Docosahexaenoic Acid (DHA): A Review Study

Abdulnabi Ali Abushita*

Chemistry Department, Faculty of Science, University of Gharyan, Libya.

مصادر ومآلات حمض الدوكوساهكسانويك (DHA): دراسة مرجعية

عبد النبي علي أبو شيتة*

قسم الكيمياء، كلية العلوم، جامعة غريان، غريان، ليبيا

*Corresponding author: abushite@gmail.com.

Received: July 09, 2026

Accepted: September 19, 2026

Published: October 05, 2026

Copyright: © 2026 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract:

Docosahexaenoic acid (DHA) is an essential omega-3 polyunsaturated fatty acid with profound importance for human health. It is a critical structural component of neuronal and retinal membranes, underpinning its vital role in cognitive function and visual acuity. While endogenous synthesis from alpha-linolenic acid is possible, the conversion rate in humans is notoriously low, making pre-formed DHA from the diet indispensable. This mini-review consolidates current knowledge on the sources and fates of DHA. We first detail its primary origins, ranging from marine fish and seafood to algal oils, which serve as a sustainable, vegetarian alternative. The review then delineates the metabolic journeys of DHA upon ingestion: its incorporation into phospholipid membranes of target tissues, its role as a precursor for potent specialized pro-resolving mediators that quell inflammation, and its catabolism for energy. By synthesizing the pathways from intake to utilization, this review highlights the critical importance of adequate DHA intake for maintaining physiological functions across the lifespan and informs nutritional strategies to prevent deficiency.

Keywords: Docosahexaenoic Acid, DHA, Omega-3, Sources, Metabolism, Bioactive Lipids, Brain Health, Inflammation.

الملخص:

يُعد حمض الدوكوساهيكسانويك (DHA) حمضاً دهنيّاً أساسياً من نوع أوميغا-3 متعدد غير مشبع، ويتمتع بأهمية بالغة لصحة الإنسان. فهو يشكل مكوناً هيكلياً حيوياً لأغشية الخلايا العصبية وشبكية العين، مما يرسخ دوره الجوهري في الوظائف الإدراكية وحدّة الإبصار. ورغم إمكانية تخليقه داخلياً في الجسم من حمض ألفا-لينولينيك، إلا أن معدل التحويل لدى البشر منخفض للغاية، مما يجعل الحصول على حمض DHA جاهزاً (مُصنّعاً مسبقاً) من خلال النظام الغذائي أمراً لا غنى عنه. تستعرض هذه المقالة الموجزة المعارف الراهنة حول مصادر حمض DHA ومآلاته الحيوية؛ إذ تتناول في البداية مصادره الرئيسية، بدءاً من الأسماك البحرية والمأكولات البحرية ووصولاً إلى زيوت الطحالب التي تُعد بديلاً نباتياً مستداماً. ثم توضح المقالة المسارات الأيضية لحمض DHA عقب تناوله، بما في ذلك دمجه في الأغشية الفوسفوليبيدية للأنسجة المستهدفة، ودوره كطليعة لإنتاج وسائط متخصصة وفعالة تعمل على إنهاء الالتهاب (pro-resolving mediators)، فضلاً عن تقويضه (تفكيكه) لإنتاج الطاقة. ومن خلال الربط بين المسارات المختلفة - بدءاً من التناول ووصولاً إلى الاستفادة الحيوية - تُبرز هذه المقالة الأهمية القصوى لتناول كميات كافية من حمض DHA للحفاظ على الوظائف الفسيولوجية طوال مراحل العمر، كما تقدم رؤية تدعم الاستراتيجيات الغذائية الرامية إلى الوقاية من نقصه.

الكلمات المفتاحية: حمض الدوكوساهيكسانويك، DHA، أوميغا-3، المصادر، الأيض، دهون نشطة حيويًا، صحة الدماغ، الالتهاب.

Brief Context:

Docosahexaenoic acid (DHA; 22:6n-3) is a critical long-chain omega-3 polyunsaturated fatty acid (LC-PUFA) that is indispensable for human health and development. Its unique structure, featuring a 22-carbon chain with six double bonds, confers exceptional fluidity to cell membranes, which is vital for the function of highly active tissues [1,2].

DHA is most renowned for its profound role in the nervous system. It is the most abundant LC-PUFA in the brain and retina, where it is selectively incorporated into phospholipids of neuronal membranes and synaptic vesicles. This high concentration is essential for supporting neurogenesis, synaptic transmission, and signal transduction [1,3]. Furthermore, DHA is a crucial precursor for a class of potent bioactive mediators, known as specialized pro-resolving mediators (SPMs), which are key players in actively resolving inflammatory processes and promoting tissue repair [4].

Despite its critical importance, humans inefficiently synthesize DHA from the plant-based precursor, alpha-linolenic acid (ALA), due to limited enzymatic activity, particularly of the Δ -6 desaturase enzyme [5]. This makes the consumption of pre-formed DHA from dietary or supplemental sources essential for maintaining adequate tissue levels and supporting its diverse physiological roles throughout life.

Problem/Significance:

The profound significance of docosahexaenoic acid (DHA) is underscored by a critical physiological problem: its absolute necessity for optimal neurological development, cognitive function, and visual acuity stands in stark contrast to the human body's severely limited ability to synthesize it *de novo*.

DHA is not merely a passive structural component; it is dynamically involved in fundamental processes. During gestation and infancy, it is rapidly accreted in the brain, where it supports neurite outgrowth, synaptogenesis, and the formation of complex neural networks [6]. In the adult brain, DHA maintains synaptic plasticity and membrane integrity, with higher levels correlating with improved cognitive performance and a potentially reduced risk of neurodegenerative decline [7]. Simultaneously, in the retina, DHA constitutes over 50% of the photoreceptor outer segment membranes, enabling efficient phototransduction and visual signal processing [8].

This high demand, however, cannot be met by endogenous production. The biosynthesis of DHA from its dietary precursor, alpha-linolenic acid (ALA), is highly inefficient in humans, with conversion rates estimated to be less than 1-5% [9,10]. This bottleneck is primarily due to the low activity of the rate-limiting Δ -6 desaturase enzyme. Consequently, the body's pool of DHA is heavily dependent on a consistent direct dietary intake of pre-formed DHA.

This creates a major public health consideration: suboptimal DHA status, particularly during critical developmental windows like pregnancy and early childhood, can have lasting consequences on brain architecture and function, while insufficiency in adulthood may contribute to increased vulnerability to cognitive decline and inflammatory pathologies. Therefore, understanding the dietary sources and metabolic fates of DHA is not just a biological inquiry but a prerequisite for effective nutritional strategies to safeguard human health across the lifespan.

This mini-review aims to synthesize current knowledge on the journey of docosahexaenoic acid (DHA) from diet to disposition. We will systematically outline its primary dietary sources and detail its complex metabolic fates, including its structural incorporation into tissues, its role as a precursor for specialized pro-resolving lipid mediators, and its catabolism for energy.

A comprehensive understanding of the dietary sources and complex metabolic fates of DHA is fundamental for shaping effective nutritional guidelines and developing targeted therapeutic strategies. This knowledge is crucial for ensuring optimal neurological and visual development, maintaining cognitive function throughout life, and mitigating the risk of chronic inflammatory and cardiovascular diseases.

Introduction:

Based on a search conducted on Scopus for the last 10 years (up to 2024), the number of scientific papers published that deal with the study of Docosahexaenoic Acid (DHA) is growing as shown on Fig. 1. The search was performed using the key term "Docosahexaenoic Acid" in the title and filtered for the publication dates, 2015, to 2024.

The publication trends that were noticed during this period are:

- **2023-2024:** Continued focus on brain health, the gut-brain axis, and the role of DHA-derived SPMs in Long COVID and post-viral inflammation.
- **2022:** Growing emphasis on sustainable sources (algae, engineered plants) and large-scale cohort studies linking DHA status to aging and cognitive decline.
- **2021:** Research into DHA's potential role in modulating immune response and inflammation related to the COVID-19 pandemic.

- **2020:** Increased studies on prenatal nutrition and early childhood development, alongside mechanistic work on specialized pro-resolving mediators (SPMs).
- **2019:** Foundational studies solidifying the link between DHA, cardiovascular health, and its triglyceride-lowering mechanisms.
- **2015:** steady increase of the number of papers dealing with DHA.




Fig. (1): Research documents per year for the period of 2015-2024, on the topic DHA (by Scopus).

The Biological Significance of Docosahexaenoic Acid (DHA):

Docosahexaenoic acid (DHA; 22:6n-3) is a long-chain omega-3 polyunsaturated fatty acid characterized by a 22-carbon backbone and six cis double bonds, the first of which is located at the third carbon from the methyl end (hence, n-3). This unique structure is the foundation of its critical biological roles. DHA is not merely a metabolic fuel; it is a fundamental and integral structural component of membrane phospholipids, particularly phosphatidylethanolamine and phosphatidylserine, in highly active tissues throughout the body [11].

Structural Role in Cellular Membranes:

The high degree of unsaturation in DHA creates a large molecular volume and significant chain flexibility. When incorporated into phospholipid bilayers, DHA prevents the fatty acid chains from packing closely together. This action increases membrane fluidity, a property essential for the proper function of embedded proteins and receptors. Fluidity facilitates conformational changes, signal transduction, and the activity of ion channels and transporters [12]. This is especially critical in the brain and retina, where DHA constitutes over 30% of the total fatty acids in gray matter phospholipids and over 50% in the photoreceptor outer segments of the retina [11,13]. In these tissues, membrane fluidity directly influences the speed and efficiency of neuronal communication and visual signal transduction.

Functional Roles in Physiology and Signaling:

Beyond its structural role, **DHA is a dynamic molecule involved in vital cellular processes:**

- **Supporting Synaptic Transmission:** In the brain, DHA is preferentially localized in synaptic membranes and vesicles. Its presence influences the release of neurotransmitters and the function of pre- and post-synaptic receptors, such as the dopamine and serotonin receptors, thereby modulating synaptic plasticity, which is the basis for learning and memory [14].
- **Precursor for Bioactive Lipid Mediators:** DHA is the direct precursor for a specialized class of lipid-derived signaling molecules known as Specialized Pro-Resolving Mediators (SPMs), which include resolvins, protectins, and maresins. Unlike classic anti-inflammatory drugs that suppress the immune response, these SPMs actively promote the resolution of inflammation by orchestrating the clearance of cellular debris and microbes and facilitating tissue repair without being immunosuppressive [15].
- **Gene Regulation:** DHA and its metabolites can act as ligands for transcription factors, such as the peroxisome proliferator-activated receptor (PPAR) family and the retinoid X receptor (RXR), thereby influencing the expression of genes involved in lipid metabolism, inflammation, and cell survival [16].

The Human Requirement and Biosynthetic Limitation:

Despite the critical importance of docosahexaenoic acid (DHA) for human physiology, endogenous synthesis is insufficient to meet the body's demands, creating a fundamental reliance on dietary intake. This bottleneck highlights the conditional essentiality of pre-formed DHA, particularly during periods of rapid growth and development.

The Inefficient Biosynthetic Pathway:

Humans possess the enzymatic machinery to synthesize DHA from the essential plant-derived omega-3 fatty acid, alpha-linolenic acid (ALA; 18:3n-3). This process occurs primarily in the liver and involves a series of elongation (adding two carbon units) and desaturation (adding double bonds) reactions. The pathway can be summarized as:

ALA (18:3n-3) → Stearidonic Acid (18:4n-3) → Eicosatetraenoic Acid (20:4n-3) → Eicosapentaenoic Acid (EPA; 20:5n-3) → Docosapentaenoic Acid (DPA; 22:5n-3) → Tetracosapentaenoic Acid (24:5n-3) → Tetracosahexaenoic Acid (24:6n-3) → DHA (22:6n-3)

The critical limitation in this pathway is the exceptionally low activity of the rate-limiting enzyme, Δ-6 desaturase (FADS2), which catalyzes the first step (conversion of ALA to Stearidonic Acid) [17, 18]. This enzyme is not only slow but is also competitively inhibited by high dietary intakes of omega-6 fatty acids (e.g., linoleic acid), which are abundant in modern Western diets. Furthermore, the final step requires a 2-carbon shortening via peroxisomal β-oxidation, adding another layer of complexity and potential inefficiency.

Quantifying the Limitation and the Dietary Imperative:

Isotopic tracer studies in humans have quantitatively demonstrated this poor conversion. The estimated overall rate of conversion from dietary ALA to DHA is consistently low, generally reported to be less than 1% in healthy adults, with some studies showing even lower rates in men compared to women [19, 20].

This profound biosynthetic limitation has several critical implications:

- **Dietary Necessity:** It establishes that consuming pre-formed DHA is the only reliable way to maintain adequate tissue levels, especially in organs like the brain and retina. While ALA is "essential" in the strictest sense, DHA is functionally essential for optimal health.
- **Life Stage Vulnerability:** The requirement for pre-formed DHA is most acute during pregnancy, lactation, and infancy. The fetal and neonatal brain undergoes rapid DHA accretion, and the maternal biosynthetic capacity is utterly insufficient to meet this demand, making maternal dietary intake crucial for offspring development [21].
- **Basis for Recommendations:** This physiological reality is the foundation for dietary recommendations from health organizations worldwide, which advise the regular consumption of DHA-rich foods (like fatty fish) or supplements (like algal or fish oil) to ensure sufficiency and support long-term health outcomes.

Objective and Scope:

Given the established biological significance of docosahexaenoic acid (DHA) and the human body's critical dependence on dietary sources to maintain adequate levels, a synthesized and updated understanding of its journey from ingestion to physiological action is paramount. While the fundamental importance of DHA is well-documented, research continues to elucidate the complexities of its bioavailability from different sources and the factors influencing its metabolic partitioning [22, 23].

The primary objective of this mini-review is to provide a consolidated and contemporary overview of the complete DHA pathway. We aim to systematically:

1. Catalog the major dietary and supplemental sources of pre-formed DHA, addressing the bioavailability of different chemical forms (e.g., triglycerides vs. phospholipids) and evaluating the promise of sustainable alternatives like algal oil [24].
2. Detail the metabolic fates of DHA upon ingestion, tracing its absorption, transport, and subsequent partitioning between three principal pathways:
 - Its structural incorporation into membrane phospholipids of key tissues, notably the brain and retina.
 - Its role as a precursor for the synthesis of potent bioactive lipid mediators, such as the specialized pro-resolving mediators (resolvins, protectins, and maresins).
 - Its catabolism via β-oxidation for energy production, a fate influenced by nutritional status and overall lipid intake.

The scope of this review is intentionally focused on the human context, bridging the gap between biochemical pathways and practical nutritional implications. By synthesizing evidence from biochemical, clinical, and public health studies, this review will serve as a concise resource for understanding how DHA intake translates into its diverse health effects. Ultimately, this work seeks to underscore why a

holistic view of DHA's "sources and fates" is indispensable for formulating effective dietary recommendations and future therapeutic strategies.

Sources of Docosahexaenoic Acid:

Given the severe limitation in endogenous synthesis, obtaining pre-formed docosahexaenoic acid (DHA) from the diet is imperative for maintaining physiological levels. DHA is predominantly found esterified in the *sn*-2 position of triacylglycerols (TAG) or phospholipids (PL), with the specific lipid form influencing its bioavailability. This section outlines the primary sources of DHA, which range from traditional marine organisms to modern fortified foods and supplements, each playing a distinct role in meeting human nutritional requirements.

Primary Natural Sources: Marine Origins:

The vast majority of bioavailable, pre-formed docosahexaenoic acid (DHA) in the human food chain originates in the marine environment. DHA is synthesized *de novo* by primary producers and then bioaccumulates through the trophic levels, ultimately reaching humans through the consumption of fish and seafood.

Fatty Fish: The Major Dietary Contributors:

Cold-water fatty fish represent the most significant and well-characterized dietary sources of DHA. Species such as salmon, mackerel, herring, sardines, and tuna have high lipid content in their flesh, a significant portion of which is comprised of DHA and EPA (eicosapentaenoic acid). These fish accumulate DHA by consuming smaller fish and zooplankton that have fed directly on marine algae. For instance, a 100-gram serving of Atlantic salmon can provide between 1,000 to 2,000 mg of DHA [25]. The DHA in these fish is primarily stored in the form of triacylglycerols (TAG) within the flesh and organs. Regular consumption of these fatty fish is consistently linked in epidemiological studies to improved cardiovascular and cognitive health outcomes.

Seafood: Shellfish and Crustaceans:

Beyond fatty fish, a diverse range of seafood provides valuable amounts of DHA, albeit often in lower total quantities per serving. **This category includes:**

- **Shellfish:** Oysters, mussels, and clams.
- **Crustaceans:** Shrimp, krill, and crab.

A key distinction for many of these sources, particularly krill, is that a larger proportion of their DHA is incorporated into phospholipids (PL) rather than TAG [26]. Some research suggests that the phospholipid form may enhance the bioavailability and efficiency of DHA incorporation into tissues, although this is an area of ongoing investigation [27].

Marine Algae: The Primary Producers:

All DHA in the marine food web originates from marine algae, specifically certain species of microalgae and phytoplankton. These photosynthetic organisms are the only life forms capable of synthesizing DHA in substantial quantities *de novo*. While larger seaweeds (macroalgae) contain some DHA, the most concentrated sources are specific strains of heterotrophic **microalgae**. This is critically important as it provides a sustainable and vegetarian source of pre-formed DHA. Algal oil, cultivated in controlled fermentation tanks, is now widely used in dietary supplements and infant formula, bypassing the marine food chain altogether [28]. This not only offers a solution for those who do not consume fish but also avoids concerns about oceanic pollutants (e.g., mercury, PCBs) that can be present in some fish oils, as the algal cultivation process is highly controlled and pure.

In summary, the marine ecosystem, from the base of the food web (algae) to its apex predators (large fish), provides a spectrum of sources for pre-formed DHA, each with distinct biochemical forms and ecological considerations.

Secondary and Supplemental Sources:

For individuals who do not regularly consume sufficient amounts of fatty fish or who seek to achieve specific therapeutic doses, secondary and supplemental sources of DHA are crucial. These products are designed to provide a concentrated and convenient means of increasing DHA intake, and their availability has grown significantly in response to public health recommendations.

Fish Oil Supplements: Concentrated and Standardized:

Fish oil supplements, derived from the tissues of oily fish, are the most common form of omega-3 supplementation. They are available as capsules or liquid oils and provide a concentrated, standardized dose of DHA and EPA, typically in the form of triacylglycerols (TAG) or ethyl esters. The ethyl ester form is a product of concentration and purification processes, which allows for higher doses of DHA/EPA per capsule. While some studies have suggested that the natural TAG form may have slightly higher bioavailability than ethyl esters, both are effective at raising plasma DHA levels, especially when taken with a fat-containing meal to aid absorption [29]. The primary advantage of supplements is dose control and the avoidance of potential environmental contaminants, as most commercial fish oils are molecularly distilled to remove heavy metals and pollutants.

Algal Oil Supplements: A Plant-Based Alternative from the Source:

Algal oil supplements are produced by cultivating specific strains of microalgae (e.g., *Schizochytrium sp.*, *Cryptocodinium cohnii*) in controlled bioreactors. These supplements represent a direct and sustainable source of DHA, as they bypass the marine food chain entirely. Algal oil is the primary source of DHA used in **infant formula** to mirror the DHA content of breast milk, underscoring its biological efficacy [30]. For vegetarians, vegans, and individuals concerned about the environmental impact or taste of fish oil, algal oil provides a viable and palatable alternative. Importantly, algal oils are typically rich in DHA but contain little to no EPA, which distinguishes their fatty acid profile from that of most fish oils [31].

Fortified Foods: Integrating DHA into the Daily Diet:

A growing number of **fortified foods** are being developed to increase DHA intake in the general population without requiring a change in dietary habits. This "food-first" approach involves adding DHA to common food items. **Common examples include:**

- **Eggs:** Produced by feeding hens a diet rich in DHA sources (e.g., algae, flaxseed).
- **Milk, Yogurt, and Dairy Alternatives:** Directly fortified with fish or algal oil.
- **Bread, Spreads, and Juices:** Increasingly used as carriers for DHA.
- **Infant Formula:** Universally fortified with DHA (from algal or fungal oil) and ARA (arachidonic acid) to support neurodevelopment in non-breastfed infants [32].

While the absolute amount of DHA per serving in fortified foods is often lower than in supplements, their regular consumption can significantly contribute to overall intake and help bridge the gap for populations with low fish consumption.

The Issue of Precursor Conversion: ALA to DHA:

While plant-based oils and seeds are often promoted as sources of omega-3 fatty acids, it is critical to distinguish between the short-chain precursor, alpha-linolenic acid (ALA; 18:3n-3), and the long-chain end product, docosahexaenoic acid (DHA). The metabolic pathway connecting them in humans is highly inefficient, rendering ALA an unreliable direct source for maintaining tissue DHA levels.

The Complex and Limited Metabolic Pathway:

The biosynthesis of DHA from ALA is a multi-step process involving alternating desaturation (adding double bonds) and elongation (lengthening the carbon chain) reactions. **The pathway proceeds as follows:**

1. ALA (18:3n-3) is converted to stearidonic acid (SDA; 18:4n-3) by the enzyme Δ -6 desaturase.
2. After elongation to eicosatetraenoic acid (20:4n-3), it is desaturated again by Δ -5 desaturase to form eicosapentaenoic acid (EPA; 20:5n-3).
3. EPA is then elongated to docosapentaenoic acid (DPA; 22:5n-3) and must undergo further elongation to tetracosapentaenoic acid (24:5n-3), a second Δ -6 desaturation to tetracosahexaenoic acid (24:6n-3), and finally a partial β -oxidation in peroxisomes to produce DHA (22:6n-3) [33].

This pathway is plagued by several bottlenecks. The initial step catalyzed by Δ -6 desaturase (FADS2) is the primary rate-limiting factor. This enzyme has a low affinity for ALA and is subject to competitive inhibition by high dietary intakes of linoleic acid (LA; 18:2n-6), an omega-6 fatty acid abundant in many vegetable oils (e.g., corn, sunflower, soybean oil) that characterizes modern Western diets [34].

Quantifying the Inefficiency and Its Implications:

Isotopic tracer and dietary intervention studies have consistently demonstrated that the conversion of ALA to DHA is extremely low in healthy adults. The estimated conversion efficiency is generally less than 1% in men and below 5-10% in women, with the higher rate in women potentially influenced by the effects of estrogen [35, 36].

This profound inefficiency has clear nutritional consequences:

- **Unreliable for Sufficiency:** Relying solely on ALA-rich foods like flaxseeds, chia seeds, and walnuts is not a viable strategy to achieve the tissue DHA levels associated with optimal brain and visual function. For instance, one would need to consume impractically large amounts of flaxseed oil to obtain the DHA equivalent found in a single serving of salmon.
- **Distinct Biological Roles:** ALA has its own health benefits and is an essential fatty acid, but it cannot substitute for the specific structural and signaling functions of pre-formed DHA in neural tissues.
- **Informed Dietary Choices:** This biochemical reality underscores the necessity for vegetarians, and especially vegans, to seek out a direct, pre-formed source of DHA, such as algal oil supplements, to ensure adequate status and avoid deficiency [37].

Fates of Docosahexaenoic Acid in the Human Body:

Once absorbed, docosahexaenoic acid (DHA) is distributed throughout the body and directed into distinct metabolic pathways that determine its ultimate physiological impact. The fate of this essential fatty acid is not singular; rather, it is strategically partitioned between structural, energetic, and signaling roles. This section details the complex journey of DHA, from its incorporation into cellular membranes to its transformation into potent bioactive mediators and its role in energy homeostasis.

Incorporation into Membranes ("Structural Fate"):

The predominant and most critical fate of docosahexaenoic acid (DHA) is its selective incorporation into the phospholipid bilayers of cell membranes. Following absorption and transport in the bloodstream primarily as lysophospholipids or non-esterified fatty acids bound to albumin, DHA is taken up by tissues and re-esterified by acyl-CoA synthetases into membrane phospholipids, particularly phosphatidylethanolamine (PE) and phosphatidylserine (PS) [38]. Its unique molecular structure, with six double bonds, creates a highly flexible and fluid lipid environment. This "structural fate" is not passive; it is a dynamic process that fundamentally influences cellular function in several key tissues.

Brain & Central Nervous System: Building the Mind:

The brain exhibits a remarkable selective accretion and retention of DHA. It constitutes approximately 30-40% of the polyunsaturated fatty acids in the phospholipids of gray matter, with concentrations in synaptic terminals and retinal photoreceptors being exceptionally high [39]. Here, DHA's role is multifaceted:

- **Neurite Outgrowth and Synaptogenesis:** DHA promotes the growth of neurites (axons and dendrites) and the formation of synapses, the communication points between neurons, which is crucial for building complex neural networks during development and for maintaining plasticity in the adult brain.
- **Cognitive Function:** The fluidity provided by DHA optimizes the function of membrane-bound proteins, including receptors (e.g., dopamine, serotonin) and ion channels, facilitating efficient neurotransmission. Higher brain DHA levels are correlated with improved learning, memory, and cognitive performance [40].

Retina: Enabling Vision:

The retina is one of the most DHA-enriched tissues in the body, where it comprises over 50% of the phospholipids in the outer segment membranes of rod and cone photoreceptors [41].

- **Phototransduction:** The high fluidity provided by DHA is essential for the rapid conformational changes of the G-protein-coupled receptor, rhodopsin, which is the first step in converting light into a neural signal. This makes DHA indispensable for visual acuity and the ability to see in low-light conditions.
- **Spermatozoa: Ensuring Fertility:** DHA is a major component of the phospholipids in sperm cell membranes, particularly in the tail.
- **Sperm Motility and Membrane Integrity:** The structural integrity and fluidity provided by DHA are critical for the sperm's flagellar function, enabling the vigorous and coordinated tail movements necessary for propulsion through the female reproductive tract. DHA is also crucial for the membrane fusion events during fertilization. A deficiency in DHA is linked to reduced sperm motility and male infertility [42].

β-Oxidation ("Energetic Fate"):

While the structural and signaling fates of docosahexaenoic acid (DHA) are of primary interest for its specific biological functions, a significant portion of ingested DHA is ultimately catabolized for energy production. This pathway, known as β-oxidation, represents a fundamental "energetic fate" and underscores the role of DHA as a valuable metabolic fuel.

Catabolism in Mitochondria and Peroxisomes:

DHA is a highly reduced molecule, and its complete oxidation yields substantial energy (approximately 136 ATP per molecule, based on theoretical calculations). The initial step in its catabolism often occurs in **peroxisomes**, which are specialized organelles adept at handling very long-chain and branched-chain fatty acids. Peroxisomes perform a limited number of β-oxidation cycles, shortening the DHA chain before the resulting medium-chain fatty acids are transferred to the **mitochondria**, the cell's main powerhouses, for complete oxidation to CO₂ and H₂O [43]. This peroxisomal "pruning" is particularly relevant for polyunsaturated fatty acids like DHA, which require additional enzymatic steps for full degradation.

A Regulated Fate Influenced by Nutritional Status:

The proportion of DHA directed towards β-oxidation is not fixed; it is dynamically regulated by the body's metabolic demands and nutritional status:

- **During Energy Deficit:** In states of fasting, caloric restriction, or sustained physical exertion, the body prioritizes the oxidation of all available fatty acids, including DHA, to generate ATP. Under these conditions, the catabolism of DHA for energy becomes a more significant fate [44].
- **With Excess Intake:** When dietary DHA intake surpasses the immediate requirements for membrane phospholipid remodeling and the synthesis of lipid mediators, the excess is predominantly channeled into β -oxidation pathways. This serves as a metabolic "overflow" mechanism to prevent the uncontrolled accumulation of free fatty acids [45].
- **Competition with Other Fates:** The partitioning of DHA is competitive. Under conditions of energy balance and adequate intake, the pathways for membrane incorporation and signaling molecule synthesis effectively "compete" with the oxidative pathways, preserving DHA for its specialized roles. High dietary levels of other fuels, such as carbohydrates and other fats, can also influence the rate of DHA oxidation.

Bioactive Metabolite Synthesis ("Signaling Fate"):

Beyond its structural role, docosahexaenoic acid (DHA) serves as a critical precursor for a potent class of bioactive lipid mediators that actively orchestrate the resolution of inflammation and tissue repair. This "signaling fate" represents a dynamic and powerful functional pathway, transforming DHA from a membrane component into a key regulator of the immune response. The enzymatic oxidation of DHA, primarily initiated by lipoxygenase (LOX) enzymes, gives rise to several families of specialized pro-resolving mediators (SPMs).

Key Mediators Derived from DHA:

The main classes of DHA-derived SPMs include:

- **D-series Resolvins (RvD1-RvD6):** Synthesized via a 17-lipoxygenase pathway, these mediators are potent regulators that "resolve" inflammation by stopping neutrophil infiltration, promoting macrophage clearance of cellular debris and microbes, and enhancing the production of anti-inflammatory cytokines [46].
- **Protectins:** Produced through a 15-lipoxygenase-like pathway, this family includes **Protectin D1 (PD1)**. When produced in the neural tissues, it is specifically referred to as **Neuroprotectin D1 (NPD1)**. PD1 is renowned for its potent anti-inflammatory and cytoprotective effects, particularly in reducing neutrophil infiltration and T-cell migration. NPD1, in particular, promotes neuronal survival by upregulating anti-apoptotic proteins and downregulating pro-inflammatory signaling in the brain [47].
- **Maresins (MaR1 & MaR2):** Synthesized in macrophages via a 12-lipoxygenase pathway, the name "Maresin" is derived from **Macrophage mediation resolutin**. Maresins strongly promote the transition of macrophages to a pro-resolving phenotype and stimulate tissue regeneration, playing a key role in the later stages of tissue repair [48].

Potent Roles in Inflammation and Protection:

The collective actions of these DHA-derived SPMs are paradigm-shifting, as they do not simply suppress the immune response but actively and coordinately **promote the resolution of inflammation**. Their roles include:

- **Limiting Neutrophil Infiltration:** Halting the further recruitment of pro-inflammatory neutrophils to the site of inflammation.
- **Enhancing Efferocytosis:** Promoting macrophages to phagocytose (clear) apoptotic cells, bacteria, and debris, which is a crucial step for tissue cleanup.
- **Reducing Pro-inflammatory Mediators:** Downregulating the expression of cytokines and enzymes that drive inflammation.
- **Promoting Tissue Regeneration:** Directly stimulating the repair and regeneration of damaged tissues, as exemplified by Maresins.
- **Providing Cellular Protection:** Shielding cells from oxidative stress and apoptosis, a function critically demonstrated by Neuroprotectin D1 in the brain and retina.

Implications for Health and Disease:

The journey of docosahexaenoic acid (DHA), from its dietary sources to its ultimate structural, energetic, and signaling fates, has direct and profound consequences for human health. An understanding of these pathways allows us to decipher its role in physiological maintenance and its therapeutic potential in pathological states. This section explores the critical implications of DHA status across key life stages and within the context of major chronic diseases, linking its molecular functions to tangible health outcomes.

Life Stages and Status:

The requirement for docosahexaenoic acid (DHA) is not static but fluctuates significantly throughout the human lifespan. Specific periods of rapid growth and physiological decline represent critical windows where DHA status has profound and lasting implications for health outcomes.

Pregnancy & Lactation: Building the Neurological Foundation:

The demand for DHA escalates dramatically during pregnancy and lactation to support the developing fetus and newborn. The third trimester of pregnancy and the first two years of life (a period often termed the "first 1000 days") are characterized by explosive growth and development of the brain and retina, processes that require massive accretion of DHA [49].

- **Fetal & Infant Brain Development:** The fetus is entirely dependent on maternal DHA, which is transferred across the placenta. Postpartum, DHA is supplied through breast milk. Adequate maternal DHA intake and status are consistently associated with improved cognitive outcomes in children, including better problem-solving skills, visual acuity, and communication skills. Conversely, DHA deficiency during these critical periods has been linked to suboptimal neurodevelopment [50].
- **Maternal Health:** Sufficient DHA levels may also support maternal well-being by modulating inflammatory processes and potentially reducing the risk of postpartum depression, although evidence for the latter remains an area of active research [51].

Consequently, international expert bodies recommend that pregnant and lactating women consume at least 200-300 mg of pre-formed DHA daily to support both the infant's development and their own nutritional reserves [52].

Aging: Preserving Cognitive and Sensory Function:

In later life, DHA plays a crucial role in maintaining neurological and visual integrity against age-related decline.

- **Mitigating Cognitive Decline:** The aging brain is vulnerable to oxidative stress, chronic low-grade inflammation ("inflammaging"), and neuronal loss. DHA addresses these challenges through multiple mechanisms: it maintains synaptic plasticity and membrane fluidity, supports the function of key neurotransmitters, and is the precursor for Neuroprotectin D1 (NPD1), which exerts anti-apoptotic and anti-inflammatory effects in the brain. Observational studies consistently show that higher dietary DHA intake or blood levels are associated with a reduced risk of cognitive decline, Alzheimer's disease, and other dementias [53].
- **Maintaining Retinal Health:** Age-related macular degeneration (AMD) is a leading cause of blindness in the elderly. DHA's high concentration in retinal photoreceptors is essential for maintaining their structure and function. Furthermore, its anti-inflammatory and pro-resolving properties help protect the retina from oxidative damage and inflammation, which are key drivers of AMD. The AREDS2 clinical trial found that supplementing with DHA and EPA, while not preventing AMD in the general population, may slow progression in individuals with established disease [54].

Disease Contexts:

The diverse biological fates of docosahexaenoic acid (DHA) underpin its significant role in the pathophysiology and potential management of a wide spectrum of chronic diseases. Its mechanisms of action—ranging from modulating membrane fluidity to generating pro-resolving mediators—translate into tangible therapeutic effects across several major health contexts.

Cardiovascular Health: Multi-faceted Cardio-protection:

DHA exerts several well-established benefits on cardiovascular health, contributing to reduced morbidity and mortality.

- **Triglyceride-Lowering:** DHA is a potent reducer of fasting and postprandial plasma triacylglycerol (TAG) levels, a key risk factor for cardiovascular disease. It achieves this primarily by downregulating the hepatic synthesis and secretion of very-low-density lipoproteins (VLDL) and enhancing the clearance of circulating TAG-rich lipoproteins [55].
- **Anti-arrhythmic Effects:** DHA is incorporated into the phospholipids of cardiac myocytes, where it stabilizes the electrical activity of the heart. It makes cardiomyocytes less susceptible to triggered arrhythmias by modulating the function of various ion channels, thereby reducing the risk of sudden cardiac death [56].
- **Anti-inflammatory and Anti-atherogenic Effects:** Through its role as a precursor for specialized pro-resolving mediators (SPMs) like resolvins and protectins, DHA actively resolves inflammation within the arterial wall. This helps to stabilize atherosclerotic plaques, reduce endothelial dysfunction, and prevent the progression of atherosclerosis [57].

Neuropsychiatric Disorders: From Mood to Neurodegeneration:

Epidemiological and clinical evidence links DHA status to a range of brain-related disorders.

- **Depression:** Lower blood levels of DHA are frequently observed in individuals with major depressive disorder. DHA is thought to influence serotonergic and dopaminergic neurotransmission, enhance neuroplasticity, and counter the neuroinflammation often associated with depression. Meta-analyses of clinical trials suggest that omega-3 supplementation, particularly formulations rich in EPA, can have a beneficial adjunctive effect in treating depressive symptoms [58].
- **Attention-Deficit/Hyperactivity Disorder (ADHD):** Some studies indicate that children with ADHD may have lower DHA levels compared to their peers. While results are mixed, supplementation with DHA has shown promise in improving aspects of attention, literacy, and behavior in some children with ADHD, likely through its role in supporting prefrontal cortical function and neurotransmission [59].
- **Neurodegenerative Diseases:** In conditions like Alzheimer's disease (AD), DHA deficiency may exacerbate pathological processes. DHA helps reduce the amyloid-beta burden and tau phosphorylation, two hallmarks of AD. It also supports synaptic integrity and provides resilience against oxidative stress. While large-scale prevention trials have yielded mixed results, higher dietary DHA intake is consistently associated with a lower risk of cognitive decline and AD in observational studies [60].

Inflammatory Conditions: Resolving the Fire:

The "signaling fate" of DHA is paramount in chronic inflammatory and autoimmune diseases.

- **Role of SPMs:** In diseases such as rheumatoid arthritis (RA), asthma, and inflammatory bowel disease (IBD), the normal resolution of inflammation is impaired. DHA-derived SPMs (Resolvins, Protectins, Maresins) act as "brakes" on the inflammatory response. They actively halt neutrophil infiltration, promote macrophage switching to a pro-resolving phenotype, and stimulate tissue repair without being immunosuppressive [61].
- **Clinical Implications:** This mechanism explains, in part, the symptomatic benefits observed with fish oil supplementation in RA (reduced joint pain and stiffness) and asthma (potentially reduced bronchodilator use). The action of SPMs represents a novel therapeutic approach aimed at restoring the body's natural resolution pathways rather than broadly suppressing immunity [62].

Conclusion and Future Perspectives:

Summary of Key Points:

This mini-review has synthesized the journey of docosahexaenoic acid (DHA) from its origins to its ultimate physiological roles. It is unequivocally clear that DHA, a long-chain omega-3 polyunsaturated fatty acid primarily sourced from the marine environment (including fatty fish, seafood, and algae), is indispensable for human health. **Its significance is not derived from a single function but from its complex metabolic partitioning into three critical fates:**

- its **structural** incorporation into the phospholipid membranes of the brain, retina, and sperm, where it governs fluidity, protein function, and cellular communication;
- its **signaling** role as a precursor for specialized pro-resolving mediators (SPMs) like resolvins, protectins, and maresins, which actively orchestrate the resolution of inflammation and tissue repair; and
- its **energetic** oxidation to fuel cellular processes, a fate that becomes more prominent during energy deficit or dietary surplus. The body's profound inability to synthesize DHA *de novo* from plant-based precursors makes a consistent dietary supply of pre-formed DHA a non-negotiable requirement for maintaining these vital pathways.

Gaps, Challenges, and Future Research:

Despite significant advances, **several frontiers in DHA research demand further exploration (63):**

- **Optimizing Sustainable Sources:** With concerns over ocean stocks and environmental contaminants, the development of sustainable sources is paramount. Future work must focus on advancing **algal farming** technologies, including strain selection, bioreactor design, and lipid extraction methods, to improve yield, reduce costs, and make algal DHA a widely accessible and economically viable option for global nutrition.
- **Understanding Individual Variability:** A one-size-fits-all approach to DHA intake is likely insufficient. There is a pressing need to understand the genetic (e.g., *FADS* cluster polymorphisms), physiological, and lifestyle factors that govern an individual's capacity to absorb, transport, and utilize DHA. Unraveling this variability is the key to developing **personalized nutritional recommendations** that optimize DHA status based on an individual's unique metabolic profile.

- **Harnessing the Therapeutic Potential of SPMs:** The discovery of DHA-derived SPMs has opened a new therapeutic frontier. Future research must transition from basic biology to clinical application. This includes elucidating their precise mechanisms of action, developing stable analogs for pharmaceutical use, and conducting rigorous human trials to evaluate their efficacy in treating chronic inflammatory diseases (e.g., rheumatoid arthritis, inflammatory bowel disease), neurodegenerative conditions, and resolving non-healing wounds.

Final Take-Home Message:

In conclusion, DHA is far more than a simple dietary fat; it is a fundamental bioactive molecule whose diverse fates are woven into the fabric of human physiology, from the development of the mind to the maintenance of health in aging. The evidence compellingly reinforces that ensuring **an** adequate intake of pre-formed DHA throughout life—**via diet** or supplementation—is a critical investment in lifelong neurological integrity, visual function, and metabolic resilience. As research continues to address existing challenges, the overarching message remains clear: supporting the body's demand for DHA is a cornerstone of preventive medicine and a crucial strategy for promoting optimal health across the lifespan.

References:

1. Lauritzen, L., Hansen, P. S., Jørgensen, M. H., & Michaelsen, K. F. (2001). The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. *Progress in Lipid Research*, 40(1-2), 1–94.
2. Stillwell, W., & Wassall, S. R. (2003). Docosahexaenoic acid: membrane properties of a unique fatty acid. *Chemistry and Physics of Lipids*, 126(1), 1–27.
3. Bazinet, R. P., & Layé, S. (2014). Polyunsaturated fatty acids and their metabolites in brain function and disease. *Nature Reviews Neuroscience*, 15(12), 771–785.
4. Serhan, C. N., & Levy, B. D. (2018). Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. *Journal of Clinical Investigation*, 128(7), 2657–2669.
5. Burdge, G. C., & Calder, P. C. (2005). Conversion of α -linolenic acid to longer-chain polyunsaturated fatty acids in human adults. *Reproduction, Nutrition, Development*, 45(5), 581–597.
6. Lauritzen, L., et al. (2016). DHA Effects in Brain Development and Function. *Nutrients*, 8(1), 6.
7. Dyall, S. C. (2015). Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. *Frontiers in Aging Neuroscience*, 7, 52.
8. SanGiovanni, J. P., & Chew, E. Y. (2005). The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. *Progress in Retinal and Eye Research*, 24(1), 87–138.
9. Burdge, G. C., & Calder, P. C. (2005). Conversion of α -linolenic acid to longer-chain polyunsaturated fatty acids in human adults. *Reproduction, Nutrition, Development*, 45(5), 581–597.
10. Plourde M, Cunnane SC. Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. *Appl Physiol Nutr Metab*. 2007 Aug;32(4):619-634. doi: 10.1139/h07-034. Erratum in: *Appl Physiol Nutr Metab*. 2008 Feb;33(1):228-9. PMID: 17622276.
11. Stillwell, W., & Wassall, S. R. (2003). Docosahexaenoic acid: membrane properties of a unique fatty acid. *Chemistry and Physics of Lipids*, 126(1), 1–27. [https://doi.org/10.1016/s0009-3084\(03\)00101-4](https://doi.org/10.1016/s0009-3084(03)00101-4)
12. Feller, S. E., Gawrisch, K., & MacKerell, A. D. (2002). Polyunsaturated fatty acids in lipid bilayers: intrinsic and environmental contributions to their unique physical properties. *Journal of the American Chemical Society*, 124(2), 318–326. <https://doi.org/10.1021/ja0118340>
13. SanGiovanni, J. P., & Chew, E. Y. (2005). The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. *Progress in Retinal and Eye Research*, 24(1), 87–138. <https://doi.org/10.1016/j.preteyeres.2004.06.002>
14. Bazinet, R. P., & Layé, S. (2014). Polyunsaturated fatty acids and their metabolites in brain function and disease. *Nature Reviews Neuroscience*, 15(12), 771–785. <https://doi.org/10.1038/nrn3820>
15. Serhan, C. N., & Levy, B. D. (2018). Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. *Journal of Clinical Investigation*, 128(7), 2657–2669. <https://doi.org/10.1172/JCI97943>
16. Deckelbaum, R. J., Worgall, T. S., & Seo, T. (2006). n-3 fatty acids and gene expression. *The American Journal of Clinical Nutrition*, 83(6 Suppl), 1520S-1525S. <https://doi.org/10.1093/ajcn/83.6.1520S>
17. Burdge, G. C., & Calder, P. C. (2005). Conversion of α -linolenic acid to longer-chain polyunsaturated fatty acids in human adults. *Reproduction, Nutrition, Development*, 45(5), 581–597. <https://doi.org/10.1051/rnd:2005047>

18. Sprecher, H. (2000). Metabolism of highly unsaturated n-3 and n-6 fatty acids. *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids*, 1486(2-3), 219–231. [https://doi.org/10.1016/s1388-1981\(00\)00077-9](https://doi.org/10.1016/s1388-1981(00)00077-9)
19. Plourde, M., & Cunnane, S. C. (2007). Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. *Applied Physiology, Nutrition, and Metabolism*, 32(4), 619–634. <https://doi.org/10.1139/H07-034>
20. Brenna, J. T., Salem, N., Sinclair, A. J., & Cunnane, S. C. (2009). α -Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. *Prostaglandins, Leukotrienes and Essential Fatty Acids*, 80(2-3), 85–91. <https://doi.org/10.1016/j.plefa.2009.01.004>
21. Koletzko, B., Lien, E., Agostoni, C., Böhles, H., Campoy, C., Cetin, I., ... & Uauy, R. (2008). The roles of long-chain polyunsaturated fatty acids in pregnancy, lactation and infancy: review of current knowledge and consensus recommendations. *Journal of Perinatal Medicine*, 36(1), 5–14. <https://doi.org/10.1515/JPM.2008.001>
22. Calder, P. C. (2016). Docosahexaenoic Acid. *Annals of Nutrition and Metabolism*, 69(1), 7–21. <https://doi.org/10.1159/000448262>
23. Dyall, S. C. (2015). Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. *Frontiers in Aging Neuroscience*, 7, 52. <https://doi.org/10.3389/fnagi.2015.00052>
24. Kagan, M. L., & West, A. L. (2020). Algal Oil as a Source of Omega-3 Fatty Acids. In J. Jacob-Lopes, L. Q. Zepka, & M. I. Queiroz (Eds.), *Handbook of Microalgae-Based Processes and Products*. Academic Press. <https://doi.org/10.1016/B978-0-12-818536-0.00013-8>
25. USDA FoodData Central. (2019). Fish, salmon, Atlantic, farmed, cooked, dry heat. U.S. Department of Agriculture. <https://fdc.nal.usda.gov>
26. Ulven, S. M., & Holven, K. B. (2015). Comparison of bioavailability of krill oil versus fish oil and health effect. *Vascular Health and Risk Management*, 11, 511–524. <https://doi.org/10.2147/VHRM.S85165>
27. Schuchardt, J. P., Schneider, I., Meyer, H., Neubronner, J., von Schacky, C., & Hahn, A. (2011). Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations--a comparative bioavailability study of fish oil vs. krill oil. *Lipids in Health and Disease*, 10, 145. <https://doi.org/10.1186/1476-511X-10-145>
28. Kagan, M. L., & West, A. L. (2020). Algal Oil as a Source of Omega-3 Fatty Acids. In J. Jacob-Lopes, L. Q. Zepka, & M. I. Queiroz (Eds.), *Handbook of Microalgae-Based Processes and Products*. Academic Press. <https://doi.org/10.1016/B978-0-12-818536-0.00013-8>
29. Dyerberg, J., Madsen, P., Møller, J. M., Aardestrup, I., & Schmidt, E. B. (2010). Bioavailability of marine n-3 fatty acid formulations. *Prostaglandins, Leukotrienes and Essential Fatty Acids*, 83(3), 137–141. <https://doi.org/10.1016/j.plefa.2010.06.007>
30. Ryan, A. S., & Astwood, J. D. (2010). Effects of long-chain polyunsaturated fatty acid supplementation on neurodevelopment in infancy: a systematic review of randomized controlled trials. *Lipids*, 45(10), 901–910. <https://doi.org/10.1007/s11745-010-3455-7>
31. Kagan, M. L., & West, A. L. (2020). Algal Oil as a Source of Omega-3 Fatty Acids. In J. Jacob-Lopes, L. Q. Zepka, & M. I. Queiroz (Eds.), *Handbook of Microalgae-Based Processes and Products*. Academic Press. <https://doi.org/10.1016/B978-0-12-818536-0.00013-8>
32. Koletzko, B., Baker, S., Cleghorn, G., Neto, U. F., Gopalan, S., Hernell, O., ... & Zlotkin, S. (2005). Global standard for the composition of infant formula: recommendations of an ESPGHAN coordinated international expert group. *Journal of Pediatric Gastroenterology and Nutrition*, 41(5), 584–599. <https://doi.org/10.1097/01.mpg.0000187817.38836.42>
33. Sprecher, H. (2000). Metabolism of highly unsaturated n-3 and n-6 fatty acids. *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids*, 1486(2-3), 219–231. [https://doi.org/10.1016/s1388-1981\(00\)00077-9](https://doi.org/10.1016/s1388-1981(00)00077-9)
34. Burdge, G. C., & Calder, P. C. (2005). Conversion of α -linolenic acid to longer-chain polyunsaturated fatty acids in human adults. *Reproduction, Nutrition, Development*, 45(5), 581–597. <https://doi.org/10.1051/rnd:2005047>
35. Plourde, M., & Cunnane, S. C. (2007). Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. *Applied Physiology, Nutrition, and Metabolism*, 32(4), 619–634. <https://doi.org/10.1139/H07-034>
36. Brenna, J. T., Salem, N., Sinclair, A. J., & Cunnane, S. C. (2009). α -Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. *Prostaglandins, Leukotrienes and Essential Fatty Acids*, 80(2-3), 85–91. <https://doi.org/10.1016/j.plefa.2009.01.004>

37. Saunders, A. V., Davis, B. C., & Garg, M. L. (2013). Omega-3 polyunsaturated fatty acids and vegetarian diets. *The Medical Journal of Australia*, 199(S4), S22–S26. <https://doi.org/10.5694/mja11.11507>
38. Lagarde, M., Bernoud, N., Brossard, N., Lemaitre-Delaunay, D., Thiès, F., Croset, M., & Lecerf, J. (2001). Lysophosphatidylcholine as a preferred carrier form of docosahexaenoic acid to the brain. *Journal of Molecular Neuroscience*, 16(2-3), 201–204. <https://doi.org/10.1385/JMN:16:2-3:201>
39. Stillwell, W., & Wassall, S. R. (2003). Docosahexaenoic acid: membrane properties of a unique fatty acid. *Chemistry and Physics of Lipids*, 126(1), 1–27. [https://doi.org/10.1016/s0009-3084\(03\)00101-4](https://doi.org/10.1016/s0009-3084(03)00101-4)
40. Bazinet, R. P., & Layé, S. (2014). Polyunsaturated fatty acids and their metabolites in brain function and disease. *Nature Reviews Neuroscience*, 15(12), 771–785. <https://doi.org/10.1038/nrn3820>
41. SanGiovanni, J. P., & Chew, E. Y. (2005). The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. *Progress in Retinal and Eye Research*, 24(1), 87–138. <https://doi.org/10.1016/j.preteyeres.2004.06.002>
42. Aksoy, Y., Aksoy, H., Altinkaynak, K., Aydin, H. R., & Ozkan, A. (2006). Sperm fatty acid composition in subfertile men. *Prostaglandins, Leukotrienes and Essential Fatty Acids*, 75(2), 75–79. <https://doi.org/10.1016/j.plefa.2006.06.002>
43. Wanders, R. J., Waterham, H. R., & Ferdinandusse, S. (2016). Metabolic Interplay between Peroxisomes and Other Subcellular Organelles Including Mitochondria and the Endoplasmic Reticulum. *Frontiers in Cell and Developmental Biology*, 3, 83. <https://doi.org/10.3389/fcell.2015.00083>
44. Ghasemi Fard, S., Wang, F., Sinclair, A. J., Elliott, G., & Turchini, G. M. (2019). How does high DHA fish oil affect health? A systematic review of evidence. *Critical Reviews in Food Science and Nutrition*, 59(11), 1684–1727. <https://doi.org/10.1080/10408398.2018.1425978>
45. Kaur, G., Cameron-Smith, D., Garg, M., & Sinclair, A. J. (2011). Docosapentaenoic acid (22:5n-3): a review of its biological effects. *Progress in Lipid Research*, 50(1), 28–34. <https://doi.org/10.1016/j.plipres.2010.07.004>
46. Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., & Moussignac, R. L. (2002). Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. *The Journal of Experimental Medicine*, 196(8), 1025–1037. <https://doi.org/10.1084/jem.20020760>
47. Bazan, N. G. (2018). Docosanoids and elovanoids from omega-3 fatty acids are pro-homeostatic modulators of inflammatory responses, cell damage and neuroprotection. *Molecular Aspects of Medicine*, 64, 18–33. <https://doi.org/10.1016/j.mam.2018.09.003>
48. Serhan, C. N., & Levy, B. D. (2018). Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. *Journal of Clinical Investigation*, 128(7), 2657–2669. <https://doi.org/10.1172/JCI97943>
49. Clandinin, M. T., Chappell, J. E., Leong, S., Heim, T., Swyer, P. R., & Chance, G. W. (1980). Extranutrient fatty acid accretion in infant brain: implications for fatty acid requirements. *Early Human Development*, 4(2), 131–138. [https://doi.org/10.1016/0378-3782\(80\)90016-5](https://doi.org/10.1016/0378-3782(80)90016-5)
50. Gould, J. F., Smithers, L. G., & Makrides, M. (2013). The effect of maternal omega-3 (n-3) LCPUFA supplementation during pregnancy on early childhood cognitive and visual development: a systematic review and meta-analysis of randomized controlled trials. *The American Journal of Clinical Nutrition*, 97(3), 531–544. <https://doi.org/10.3945/ajcn.112.045781>
51. Middleton, P., Gomersall, J. C., Gould, J. F., Shepherd, E., Olsen, S. F., & Makrides, M. (2018). Omega-3 fatty acid addition during pregnancy. *Cochrane Database of Systematic Reviews*, 11(11), CD003402. <https://doi.org/10.1002/14651858.CD003402.pub3>
52. Koletzko, B., Cetin, I., & Brenna, J. T. (2007). Dietary fat intakes for pregnant and lactating women. *The British Journal of Nutrition*, 98(5), 873–877. <https://doi.org/10.1017/S0007114507764747>
53. Yassine, H. N., Braskie, M. N., Mack, W. J., Castor, K. J., Fonteh, A. N., Schneider, L. S., ... & Chui, H. C. (2017). Association of Docosahexaenoic Acid Supplementation with Alzheimer Disease Stage in Apolipoprotein E ε4 Carriers: A Review. *JAMA Neurology*, 74(3), 339–347. <https://doi.org/10.1001/jamaneurol.2016.4899>
54. Age-Related Eye Disease Study 2 (AREDS2) Research Group. (2013). Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: The Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. *JAMA*, 309(19), 2005–2015. <https://doi.org/10.1001/jama.2013.4997>

55. Skulas-Ray, A. C., Wilson, P. W. F., Harris, W. S., Brinton, E. A., Kris-Etherton, P. M., Richter, C. K., ... & Welty, F. K. (2019). Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. *Circulation*, 140(12), e673–e691. <https://doi.org/10.1161/CIR.0000000000000709>
56. Mozaffarian, D., & Wu, J. H. (2011). Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. *Journal of the American College of Cardiology*, 58(20), 2047–2067. <https://doi.org/10.1016/j.jacc.2011.06.063>
57. Endo, J., & Arita, M. (2016). Cardioprotective mechanism of omega-3 polyunsaturated fatty acids. *Journal of Cardiology*, 67(1), 22–27. <https://doi.org/10.1016/j.jjcc.2015.08.002>
58. Liao, Y., Xie, B., Zhang, H., He, Q., Guo, L., Subramanieapillai, M., ... & McIntyre, R. S. (2019). Efficacy of omega-3 PUFAs in depression: A meta-analysis. *Translational Psychiatry*, 9(1), 190. <https://doi.org/10.1038/s41398-019-0515-5>.
59. Bloch, M. H., & Qawasmi, A. (2011). Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. *Journal of the American Academy of Child and Adolescent Psychiatry*, 50(10), 991–1000. <https://doi.org/10.1016/j.jaac.2011.06.008>.
60. Yassine, H. N., et al. (2017). Association of Docosahexaenoic Acid Supplementation with Alzheimer Disease Stage in Apolipoprotein E ϵ 4 Carriers: A Review. *JAMA Neurology*, 74(3), 339–347. <https://doi.org/10.1001/jamaneurol.2016.4899>.
61. Chiurchiù, V., Leuti, A., & Maccarrone, M. (2018). Bioactive Lipids and Chronic Inflammation: Managing the Fire Within. *Frontiers in Immunology*, 9, 38. <https://doi.org/10.3389/fimmu.2018.00038>.
62. Calder, P. C. (2017). Omega-3 fatty acids and inflammatory processes: from molecules to man. *Biochemical Society Transactions*, 45(5), 1105–1115. <https://doi.org/10.1042/BST20160474>.
63. Hei A and Sanahanbi L (2023). DHA (Docosahexaenoic Acid): A Biomolecule with Diverse Roles and Health Benefits. *Dietary Supplements - Challenges and Future Research*. IntechOpen. Available at: <http://dx.doi.org/10.5772/intechopen.109677>.